Achieve Life Sciences Inc. (SP4P)
XDUS 
Summary
SP4P Chart
Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)
Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. ACHV's FDA setback was manufacturing-related, not efficacy or safety, with two successful Phase 3 trials and over 1,500 exposures supporting its profile. ACHV is well-capitalized, holding $188 million in cash post-private placement, sufficient to fund the NDA resubmission and initial launch activities.
Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis
Achieve Life Sciences is navigating a manufacturing reset for cytisinicline following a Complete Response Letter citing facility compliance, not efficacy or safety concerns. I remain bullish on ACHV, contingent on resolving manufacturing issues and leveraging a funded transition to commercialization, not market expansion or first-line displacement. ACHV's cash runway, bolstered by $180M upfront financing, appears sufficient through potential FDA approval in 1H 2027, but dilution and arbitration risks must be monitored.
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company's Chief Legal Officer, would act as secretary and record the minutes.
Achieve Life Sciences Inc. (SP4P) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Achieve Life Sciences Inc. ever had a stock split?
Achieve Life Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Andrew D. Goldberg CEO | XDUS Exchange | US0044685008 ISIN |
| US Country | 28 Employees | - Last Dividend | 3 Aug 2017 Last Split | 13 Oct 1995 IPO Date |
Overview
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapeutic solutions for smoking cessation and nicotine addiction. Operating in Canada, the United States, and the United Kingdom, the company focuses on addressing the global smoking health epidemic through its innovative product, cytisinicline. Leveraging license agreements with entities such as Sopharma AD and the University of Bristol, Achieve Life Sciences is committed to providing a scientifically backed, plant-based alternative to nicotine replacement therapies. Based in Vancouver, Canada, the company aims to transform the treatment landscape for individuals looking to overcome nicotine dependency.
Products and Services
- Cytisinicline:
Achieve Life Sciences' flagship product, Cytisinicline, is a plant-based alkaloid with a mechanism of action that focuses on nicotine receptors in the brain. By interacting with these receptors, Cytisinicline aims to alleviate the severity of nicotine withdrawal symptoms, making it a promising therapy for individuals seeking to quit smoking. This innovative approach to smoking cessation underscores the company's dedication to addressing nicotine addiction with alternatives derived from nature, setting a new standard in the therapeutic domain.
Contact Information
